Pharmacotherapy options for cataplexy

Expert Opinion on Pharmacotherapy

Volumn 14, Issue 7, 2013, Pages 895-903

  Lopez, Régis ^a   Dauvilliers, Yves ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

Author keywords

Adrenergic; Antidepressant; Cataplexy; Hypocretin; Narcolepsy; REM sleep; Sodium oxybate

Indexed keywords

4 AMINOBUTYRALDEHYDE; ALEMTUZUMAB; AMPHETAMINE; ATOMOXETINE; BROFAROMINE; CITALOPRAM; CLOMIPRAMINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMMUNOGLOBULIN; MAZINDOL; METHYLPHENIDATE; MILNACIPRAN; MODAFINIL; OREXIN; OXYBATE SODIUM; PAROXETINE; PROTRIPTYLINE; REBOXETINE; SELEGILINE; SEROTONIN; VENLAFAXINE; VILOXAZINE;

AMYGDALOID NUCLEUS; CATAPLEXY; DEPRESSION; DIZZINESS; DRUG EFFICACY; DYSARTHRIA; ELECTROENCEPHALOGRAM; ENURESIS; GIGANTOCELLULAR RETICULAR NUCLEUS; HALLUCINATION; HEADACHE; HUMAN; HYPOTENSION; IN VITRO STUDY; IRRITABILITY; LOCOMOTION; MOOD DISORDER; MUSCLE TONE; NARCOLEPSY; NAUSEA; NAUSEA AND VOMITING; NEUROBIOLOGY; NIGHT SLEEP; PARASOMNIA; PHENOTYPE; REM SLEEP; RESPIRATION DEPRESSION; REVIEW; SIDE EFFECT; SWEATING; TACHYCARDIA; TENDON REFLEX; UNSPECIFIED SIDE EFFECT; WEIGHT GAIN; WEIGHT REDUCTION; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANTIDEPRESSIVE AGENTS; CATAPLEXY; DRUG THERAPY, COMBINATION; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEUROPEPTIDES; SEROTONIN UPTAKE INHIBITORS; SODIUM OXYBATE;

EID: 84876021875     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2013.783021     Document Type: Review

References (71)

1. Dauvilliers Y, Arnulf I, Mignot E. Narcolepsy with cataplexy. Lancet 2007;369(9560):499-511
2. Dauvilliers Y, Montplaisir J, Molinari N, et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001;57(11):2029-33
3. Peyron C, Faraco J, Rogers W, et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nature Med 2000;6(9):991-7
4. Billiard M, Bassetti C, Dauvilliers Y, et al. EFNS guidelines on management of narcolepsy. Eur J Neurol 2006;13(10):1035-48
5. Plazzi G, Pizza F, Palaia V, et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 2011;134(12):3480-92
6. Luppi PH, Cle'ment O, Sapin E, et al. The neuronal network responsible for paradoxical sleep and its dysfunctions causing narcolepsy and rapid eye movement (REM) behavior disorder. Sleep Med Rev 2011;15(3):153-63
7. Peever J. Control of motoneuron function and muscle tone during REM sleep, REM sleep behavior disorder and cataplexy/narcolepsy. Arch Ital Biol 2011;149(4):454-66
8. Mignot E, Nishino S, Sharp LH, et al. Heterozygosity at the canarc-1 locus can confer susceptibility for narcolepsy: induction of cataplexy in heterozygous asymptomatic dogs after administration of a combination of drugs acting on monoaminergic and cholinergic systems. J Neurosci 1993;13(3):1057-64
9. Burgess CR, Tse G, Gillis L, Peever JH. Dopaminergic regulation of sleep and cataplexy in a murine model of narcolepsy. Sleep 2010;33(10):1295-304
10. Reid MS, Tafti M, Nishino S, et al. Cholinergic regulation of cataplexy in canine narcolepsy in the pontine reticular formation is mediated by M2 muscarinic receptors. Sleep 1994;17(5):424-35
11. Nishino S, Tafti M, Reid MS, et al. Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy. J Neurosci 1995;15(7):4806-14
12. Nishino S, Mignot E. Pharmacological aspects of human and canine narcolepsy. Prog Neurobiol 1997;52(1):27-78
13. Wu MF, John J, Boehmer L, et al. Activity of dorsal raphe cells across the sleep-waking cycle and during cataplexy in narcoleptic dogs. J Physiol 2004;554(1):202-15
14. Dauvilliers Y, Baumann C, Carlander B, et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003;74(12):1667-73
15. Hara J, Beuckmann CT, Nambu T, et al. Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron 2001;30(2):345-54
16. Chemelli RM, Willie JT, Sinton CM, et al. Narcolepsy in orexin Knockout Mice: molecular Genetics of Sleep Regulation. Cell 1999;98(4):437-51
17. Willie JT, Chemelli RM, Sinton CM, et al. Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron 2003;38(5):715-30
18. Poryazova R, Siccoli M, Werth E, Bassetti CL. Unusually prolonged rebound cataplexy after withdrawal of fluoxetine. Neurology 2005;65(6):967-8
19. Akimoto H, Honda Y, Takahashi Y. Pharmacotherapy in narcolepsy. Dis Nerv Syst 1960;21:704
20. Hishikawa Y, Ida H, Nakai K, Kaneko Z. Treatment of narcolepsy with imipramine (tofranil) and desmethylimipramine (pertofran). J Neurol Sci 1966;3(5):453-61
21. Linnoila M, Simpson D, Skinner T. Characteristics of therapeutic response to imipramine in cataplectic men. Am J Psychiatry 1980;137(2):237-8
22. Attacks S. Protriptyline: an effective agent in the treatment of the narcolepsy-cataplexy syndrome and hypersomnia. Am J Psychiatry 1977;134(2):183-5
23. Schachter M, Parkes J. Fluvoxamine and clomipramine in the treatment of cataplexy. J Neurol Neurosurg Psychiatry 1980;43(2):171-4
24. Shapiro WR. Treatment of cataplexy with clomipramine. Arch Neurol 1975;32(10):653-6
25. Guilleminault C, Raynal D, Takahashi S, et al. Evaluation of short-term and long-term treatment of the narcolepsy syndrome with clomipramine hydrochloride. Acta Neurol Scand 1976;54(1):71-87
26. Parkes J, Schachter M. Clomipramine and clonazepam in cataplexy. Lancet 1979;2(8151):1085-6
27. Bental E, Lavie P, Sharf B, et al. Severe hypermotility during sleep in treatment of cataplexy with clomipramine. Isr J Med Sci 1979;15(7):607-9
28. Martinez-Rodriguez J, Iranzo A, Santamaria J, et al. Status cataplecticus induced by abrupt withdrawal of clomipramine. Neurologia 2002;17(2):113-16
29. Baldessarini RJ. How do antidepressants work. In: Davis JM, Mass JW, editors. The affective disorders. American Psychiatric Press; Wachington, DC: 1983. p. 243-60
30. Henry G, Hart R, Kwentus J, Sicola M. Effects of protryptiline on vigilance and information processing in narcolepsy. Psychopharmacology (Berl) 1988;95:109-12
31. Wyatt RJ, Fram DH, Buchbinder R, Snyder F. Treatment of intractable narcolepsy with a monoamine oxidase inhibitor. N Engl J Med 1971;285(18):987-91
32. Hublin C, Partinen M, Heinonen E, et al. Selegiline in the treatment of narcolepsy. Neurology 1994;44(11):2095
33. Mayer G, Meier KE, et al. Selegeline hydrochloride treatment in narcolepsy. A double-blind, placebo-controlled study. Clin Neuropharmacol 1995;18(4):306-19
34. Hohagen F, Mayer G, Menche A, et al. Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine-a pilot study. J Sleep Res 1993;2(4):250-6
35. Langdon N, Shindler J, Parkes J, Bandak S. Fluoxetine in the treatment of cataplexy. Sleep 1986;9(2):371-3
36. Frey J, Darbonne C. Fluoxetine suppresses human cataplexy A pilot study. Neurology 1994;44(4):707
37. Schrader H, Kayed K, Markset AC, Treidene H. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo. Acta Neurol Scand 1986;74(4):297-303
38. Godbout R, Montplaisir J. The effect of zimelidine, a serotonin-reuptake blocker, on cataplexy and daytime sleepiness of narcoleptic patients. Clin Neuropharmacol 1986;9(1):46-51
39. Thirumalai SS, Shubin RA. The use of citalopram in resistant cataplexy. Sleep Med 2000;1(4):313-16
40. Sonka K, Kemlink D, Pretl M, et al. Cataplexy treated with escitalopram-clinical experience. Neuro Endocrinol Lett 2006;27(1-2):174-6
41. Smith M, Parkes J, Dahlitz M. Venlafaxine in the treatment of the narcoleptic syndrome. J Sleep Res 1996;5(Suppl 1):217
42. Plazzi G, Montagna P, Provini F, et al. Treatment of narcolepsy with cataplexy. Lancet 2007;369(9567):1081
43. Moller LR, Ostergaard Jr. Treatment with venlafaxine in six cases of children with narcolepsy and with cataplexy and hypnagogic hallucinations. J Child Adolesc Psychopharmacol 2009;19(2):197-201
44. Aran A, Einen M, Lin L, et al. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. Sleep 2010;33(11):1457-64
45. Izzi F, Placidi F, Marciani M, et al. Effective treatment of narcolepsy-cataplexy with duloxetine: a report of three cases. Sleep Med 2009;10(1):153-4
46. Sagawa Y, Inoue Y, Kaneko Y, et al. The anticataplectic effect of milnacipran, a new SNRI, on canine and human narcolepsy. Sleep Biol Rhythms 2007;5(s1):A78
47. Guilleminault C, Mancuso J, Salva M, et al. Viloxazine hydrochloride in narcolepsy: a preliminary report. Sleep 1986;9(1 Pt 2):275-9
48. Larrosa O, de la Llave Y, Bario S, et al. Stimulant and anticataplectic effects of reboxetine in patients with narcolepsy: a pilot study. Sleep 2001;24(3):282-5
49. Niederhofer H. Atomoxetine also effective in patients suffering from narcolepsy? Sleep 2005;28(9):1189
50. Goksan B, Mercan S, Karamustafalioglu O. Bupropion is effective in depression in narcolepsy. Int J Psychiatry Clin Pract 2005;9(4):289-91
51. Pistis M, Muntoni AL, Pillolla G, et al. g-Hydroxybutyric acid (GHB) and the mesoaccumbens reward circuit: evidence for GABAB receptor-mediated effects. Neuroscience 2005;131(2):465-74
52. Broughton R, Mamelak M. Effects of nocturnal gamma-hydroxybutyrate on sleep/waking patterns in narcolepsy-cataplexy. Can J Neurol Sci 1980;7(1):23-31
53. Boscolo-Berto R, Viel G, Montagnese S, et al. Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): a systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev 2012;16(5):431-43
54. Lammers G, Arends J, Declerck A, et al. Gammahydroxybutyrate and narcolepsy: a double-blind placebo-controlled study. Sleep 1993;16(3):216-20
55. Scrima L, Hartman PG, Johnson FH, Charles Hiller F. Efficacy of gamma-hydroxybutyrate versus placebo in treating narcolepsy-cataplexy: double-blind subjective measures. Biol psychiatry 1989;26(4):331-43
56. Group UXMS. A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 2002;25(1):42-9
57. Black J, Houghton WC. Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 2006;29(7):939-46
58. Mignot E, Renaud A, Nishino S, et al. Canine cataplexy is preferentially controlled by adrenergic mechanisms: evidence using monoamine selective uptake inhibitors and release enhancers. Psychopharmacology (Berl) 1993;113(1):76-82
59. Nittur N, Konofal E, Dauvilliers Y, et al. Mazindol in narcolepsy and idiopathic and symptomatic hypersomnia refractory to stimulants: a long-term chart review. Sleep Med 2013;14(1):30-6
60. Dauvilliers Y, Carlander B, Touchon J, et al. Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset. Ann Neurol 2004;56(6):905-8
61. Lecendreux M, Maret S, Bassetti C, et al. Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy. J Sleep Res 2003;12(4):347-8
62. Plazzi G, Poli F, Franceschini C, et al. Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy. J Neurol 2008;255(10):1549-54
63. Fronczek R, Verschuuren J, Lammers GJ. Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol 2007;254(11):1607-8
64. Chen W, Black J, Call P, Mignot E. Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis. Ann Neurol 2005;58(3):489-90
65. Pincherle A, Villani F, Ferini Strambi L, et al. Immunoadsorption for the treatment of narcolepsy with cataplexy. Neurol Sci 2008;29(6):499-500
66. Dauvilliers Y, Abril B, Mas E, et al. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 2009;73(16):1333-4
67. Dauvilliers Y. Follow-up of four narcolepsy patients treated with intravenous immunoglobulins. Ann Neurol 2006;60(1):153
68. Donjacour CEHM, Lammers GJ. A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy. J Sleep Res 2012;21(4):479-80
69. Lin JS, Dauvilliers Y, Arnulf I, et al. An inverse agonist of the histamine H (3) receptor improves wakefulness in narcolepsy: studies in orexin-/-mice and patients. Neurobiol Dis 2008;30(1):74-83
70. Deadwyler SA, Porrino L, Siegel JM, Hampson RE. Systemic and nasal delivery of orexin-A (Hypocretin-1) reduces the effects of sleep deprivation on cognitive performance in nonhuman primates. J Neurosci 2007;27(52):14239-47
71. Baier PC, Weinhold SL, Huth V, et al. Olfactory dysfunction in patients with narcolepsy with cataplexy is restored by intranasal Orexin A (Hypocretin-1). Brain 2008;131(10):2734-41